- Home
- CBLL vs DNTH Comparison
CBLL vs DNTH Comparison
Compare CBLL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBLL
- DNTH
- Stock Information
- Founded
- CBLL 2014
- DNTH 2015
- Country
- CBLL United States
- DNTH United States
- Employees
- CBLL N/A
- DNTH N/A
- Industry
- CBLL
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CBLL
- DNTH Health Care
- Exchange
- CBLL Nasdaq
- DNTH Nasdaq
- Market Cap
- CBLL 710.2M
- DNTH 651.8M
- IPO Year
- CBLL 2024
- DNTH N/A
- Fundamental
- Price
- CBLL $12.06
- DNTH $24.30
- Analyst Decision
- CBLL Strong Buy
- DNTH Strong Buy
- Analyst Count
- CBLL 6
- DNTH 8
- Target Price
- CBLL $33.00
- DNTH $54.00
- AVG Volume (30 Days)
- CBLL 353.5K
- DNTH 362.9K
- Earning Date
- CBLL 08-05-2025
- DNTH 08-07-2025
- Dividend Yield
- CBLL N/A
- DNTH N/A
- EPS Growth
- CBLL N/A
- DNTH N/A
- EPS
- CBLL N/A
- DNTH N/A
- Revenue
- CBLL $77,419,000.00
- DNTH $4,854,000.00
- Revenue This Year
- CBLL $33.98
- DNTH N/A
- Revenue Next Year
- CBLL $28.82
- DNTH N/A
- P/E Ratio
- CBLL N/A
- DNTH N/A
- Revenue Growth
- CBLL 42.16
- DNTH 17.87
- 52 Week Low
- CBLL $10.01
- DNTH $13.37
- 52 Week High
- CBLL $32.75
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- CBLL 35.66
- DNTH 69.50
- Support Level
- CBLL $11.35
- DNTH $19.84
- Resistance Level
- CBLL $12.60
- DNTH $21.18
- Average True Range (ATR)
- CBLL 0.78
- DNTH 1.58
- MACD
- CBLL 0.03
- DNTH 0.39
- Stochastic Oscillator
- CBLL 17.97
- DNTH 89.88
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.